CD274 and lung carcinoma: We obtained 32 publications including the report by Ng et al.[20] Most of these publications are on the use of PD-1 drugs in lung cancer, in particular on PD-L1 expression as a predictable marker for suitability of treatment by drugs that inhibit PD-1/PD-L1.